123470-47-3

Basic information

• Product Name: 2H-Benzimidazole-2-thione,5,6-difluoro-1,3-dihydro-(9CI)
• Synonyms: 2H-Benzimidazole-2-thione,5,6-difluoro-1,3-dihydro-(9CI);5,6-DIFLUORO-1H-BENZIMIDAZOLE-2-THIOL;5,6-Difluoro-1H-benzoimidazole-2-thiol
• CAS NO: 123470-47-3
• Molecular Formula: C₇H₄F₂N₂S
• Molecular Weight: 186.18
• Product Categories: BENZIMIDAZOLE
• Mol File: 123470-47-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2H-Benzimidazole-2-thione,5,6-difluoro-1,3-dihydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Benzimidazole-2-thione,5,6-difluoro-1,3-dihydro-(9CI)(123470-47-3)
• EPA Substance Registry System: 2H-Benzimidazole-2-thione,5,6-difluoro-1,3-dihydro-(9CI)(123470-47-3)

Safety Data

• Hazardous Substances Data: 123470-47-3(Hazardous Substances Data)

Usage

Structure

Heterocyclic compound with a benzimidazole ring, two fluorine atoms, and a thione functional group

Use

Primarily used in the pharmaceutical industry for its potential antimicrobial and antifungal properties

Applications

Potential in the development of new drugs and agrochemicals

Bioactivity

The presence of fluorine atoms may contribute to its bioactivity and stability

Potential

Valuable building block for the synthesis of novel compounds with potential therapeutic uses

Research

Further research and development needed to fully understand its potential biological activities and applications

Upstream product

• 75-15-0 carbon disulfide 
• 76179-40-3 2-amino-4,5-difluoroaniline 
• 458-11-7 3,4-difluoroacetanilide 
• 78056-39-0 4,5-difluoro-2-nitroaniline 
• 140-89-6 potassium ethyl xanthogenate 
• 1662-21-1 N-(3,4-difluoro-2-nitrophenyl)acetamide 

Downstream Products

• 352216-39-8 2-(5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-1-(2,4-dimethoxy-phenyl)-ethanone 
• 372187-95-6 1-(2,4-dichloro-phenyl)-2-(5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-ethanone 
• 372187-93-4 1-(4-bromo-phenyl)-2-(5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-ethanone 
• 372187-94-5 1-(4-chloro-phenyl)-2-(5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-ethanone 
• 352216-36-5 2-(5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-1-phenyl-ethanone 
• 372187-96-7 2-(1-acetyl-5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-1-phenyl-ethanone 
• 372187-97-8 2-(1-acetyl-5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-1-o-tolyl-ethanone 
• 372187-99-0 2-(1-acetyl-5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-1-(4-chloro-phenyl)-ethanone 
• 372187-98-9 2-(1-acetyl-5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-1-(4-bromo-phenyl)-ethanone 
• 372188-00-6 2-(1-acetyl-5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-1-(2,4-dichloro-phenyl)-ethanone 
• 372188-01-7 2-(1-acetyl-5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-1-(2,4-dimethoxy-phenyl)-ethanone 
• 372187-92-3 2-(5,6-difluoro-1H-benzoimidazol-2-ylsulfanyl)-1-o-tolyl-ethanone 

Relevant articles and documents

2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2-substituted proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE OR SALT THEREOF

The present invention is directed to a method for producing a cyclic diamine compound (3) or a salt thereof through the following scheme: (wherein Ar represents a phenyl group, a pyridyl group, or a pyrimidinyl group, any of which may have a substituent; X represents NH, S, or O; ring A represents a benzene ring or a pyridine ring, which may have a substituent; 1 represents an integer of 1 or 2; m represents an integer of 1 or 2; and n represents an integer of 1 to 6). The method enables synthesis of a cyclic diamine compound (3) or a salt thereof, which serves as an ACAT inhibitor, in an industrially useful manner.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

2,4-Bis (trifluoroethoxy)pyridine compound and drug containing the compound

The present invention is directed to a 2,4-bis(trifluoroethoxy)pyridine compound represented by formula (1): (wherein X1 represents a fluorine atom or a hydrogen atom) or a salt thereof, and to a drug containing the compound or the salt as an active ingredient. The compound has metabolic resistance in human liver microsome, good absorbability upon oral administration, and excellent ACAT inhibitory activity.

Human chymase inhibitors

The present invention provides a benzimidazole derivative or its. pharmaceutically permissible salt expressed by the following formula (1). Further, the present invention provides a human chymase activity inhibitor containing the substance as an active ingredient. (the ring marked with A expresses a pyridline ring or a benzene ring; X1 and X2 are each a hydrogen atom, a halogen atom, a trihalomethyl group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, or the like; B is a substituted or unsubstituted alkylene group, or the like; E is -COOR4 or the like; G is a substituted or unsubstituted alkylene group; J is a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group; and M is a sulfur atom, sulfoxidde, sulfone or the like).

HUMAN CHYMASE INHIBITORS

The present invention provides a benzimidazole derivative or its pharmaceutically permissible salt expressed by the following formula (1). Further, the present invention provides a human chymase activity inhibitor containing the substance as an active ingredient. (the ring marked with A expresses a pyridine ring or a benzene ring; X1 and X2 are each a hydrogen atom, a halogen atom, a trihalomethyl group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, or the like; B is a substituted or unsubstituted alkylene group, or the like; E is -COOR4 or the like; G is a substituted or unsubstituted alkylene group; J is a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group; and M is a sulfur atom, sulfoxide, sulfone or the like).

Fluoro-containing heterocycles. IV. Synthesis of benzimidazole derivatives

2-Mercapto-5,6-difluorobenzimidazole reacts with aliphatic and alicyclic ketones in acetic acid in the presence of catalytic amount of sulfuric acid to afford fluorinated derivatives of 2,3-disubstituted benz[4,5]imidazo[2,1-b][1,3]thiazoles. Reaction with aromatic α-haloketones occurs in another way: to furnish 2-phenylacylthio-5,6-difluorobenzimidazoles that in the system acetic anhydride - pyridine undergo cyclization into the corresponding fluorinated derivatives of benz[4,5]imidazo[2,1-b][1,3]thiazoles.

Synthesis and Cyclization of Derivatives of 3-Heterylhydrazino-2-polyfluorobenzoylacrylic Acid

Cyclization of ethyl esters of 3-heterylhydrazino-2-polyfluorobenzoylacrylic acid results either to 2-(5-polyfluorophenyl-4-ethoxycarbonylpyrazol-1-yl)benzazoles or 2-(4-polyfluorobenzoyl-5-ethoxypyrazol-1-yl)benzenes or, in the case of benzimidazolyl derivatives possessing NH fragment, to derivatives of benzimidazolo[1,2-a]pyrazolo[1,5-c]quinazoline, a new heterocyclic system.

Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors

Helicobacter pylori urease belongs to a family of highly conserved urea- hydrolyzing enzymes. A common feature of these enzymes is the presence of two Lewis acid nickel ions and a reactive cysteine residue in the active site. The H+/K+-ATPase inhibitor omeprazole is a prodrug of a sulfenamide which covalently modifies cysteine residues on the luminal side of the H+/K+- ATPase of gastric parietal cells. Omeprazole and eight analogues were selected based on their chemical, electronic, and kinetic properties, and each was incubated with viable H. pylori in phosphate-buffered saline at pH 7.4 for 30 min, after which 100 mM urea was added and the amount of ammonia formed analyzed after a further 10 min. Inhibition between 0% and 100% at a 0.1 mM concentration was observed for the different analogues and could be expressed as a function of the pK(a)-value of the pyridine, the pK(a)-value of the benzimidazole, the overall lipophilicity, and, most importantly, the rate of sulfenamide formation, in a quantitative structure-activity relationship. The inhibition was potentiated by a lower pH (favoring the formation of the sulfenamide) but abolished in the presence of β- mercaptoethanol (a scavenger of the sulfenamide). Structural analogues incapable of yielding the sulfenamide did not inhibit ammonia production. Treatment of Helicobacter felis-infected mice with 230 μmol/kg flurofamide b.i.d. for 4 weeks, known to potently inhibit urease activity in vivo, as a means of eradicating the infection, was tested and compared with the effect of 125 μmol/kg omeprazole b.i.d. for 4 weeks. Neither treatment proved efficacious.